Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Claudio Borghi & Stefano Omboni. (2014) Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update. Expert Review of Cardiovascular Therapy 12:9, pages 1055-1065.
Read now
Read now
E Van der Merwe & A Carboni. (2011) Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients. South African Family Practice 53:6, pages 525-532.
Read now
Read now
Carlos M Ferrario & Ronald D Smith. (2010) Role of olmesartan in combination therapy in blood pressure control and vascular function. Vascular Health and Risk Management 6, pages 701-709.
Read now
Read now
Giuseppe Derosa & Sibilla AT Salvadeo. (2010) Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. Integrated Blood Pressure Control 3, pages 21-30.
Read now
Read now
Roland E Schmieder, Markus Schwertfeger & Peter Bramlage. (2009) Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vascular Health and Risk Management 5, pages 991-1000.
Read now
Read now
Articles from other publishers (14)
SK Manirul Haque. (2022) Box–Behnken experimental design for optimizing the HPLC method to determine hydrochlorothiazide in pharmaceutical formulations and biological fluid. Journal of Molecular Liquids 352, pages 118708.
Crossref
Crossref
Riccardo Sarzani, Giorgia Laureti, Alessandro Gezzi, Francesco Spannella & Federico Giulietti. (2022) Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Therapeutic Advances in Chronic Disease 13, pages 204062232211027.
Crossref
Crossref
Konda Swathi, G Lakshmi Manasa, R Munemma & B Nikitha. (2021) Method development and Validation for Estimation of Irbesartan and Hydrochlorothiazide in Tablet Dosage form by using RPHPLC. Journal of Physics: Conference Series 1817:1, pages 012029.
Crossref
Crossref
David Spirk, Sarah Noll, Michel Burnier, Stefano Rimoldi, Georg Noll & Isabella Sudano. (2020) First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH). Frontiers in Cardiovascular Medicine 7.
Crossref
Crossref
Stefano Omboni, Ettore Malacco, Claudio Napoli, Pietro Amedeo Modesti, Athanasios Manolis, Gianfranco Parati, Enrico Agabiti-Rosei & Claudio Borghi. (2017) Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized “Z” Studies. Advances in Therapy 34:4, pages 784-798.
Crossref
Crossref
Kun Hua, Guang Hao & Wei Li. (2017) Cardiovascular outcomes of lifestyle intervention in hypertensive patients with antihypertensive agents. International Journal of Cardiology 227, pages 751-756.
Crossref
Crossref
Guido Grassi, Gino Seravalle, Gianmaria Brambilla, Raffaella Dell’Oro, Fosca Quarti Trevano, Francesco Fici, Luc van Bortel & Giuseppe Mancia. (2016) Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. Advances in Therapy 33:12, pages 2173-2187.
Crossref
Crossref
Alison J. O’Donnell, Hillary R. Bogner, Peter F. Cronholm, Katherine Kellom, Michelle Miller-Day, Heather F. de Vries McClintock, Elise M. Kaye & Robert Gabbay. (2016) Stakeholder Perspectives on Changes in Hypertension Care Under the Patient-Centered Medical Home. Preventing Chronic Disease 13.
Crossref
Crossref
María Esther Rubio-Ruiz, Israel Pérez-Torres, María Elena Soto, Gustavo Pastelín & Verónica Guarner-Lans. (2014) Aging in blood vessels. Medicinal agents FOR systemic arterial hypertension in the elderly. Ageing Research Reviews 18, pages 132-147.
Crossref
Crossref
K. Leon, A. El hadidy, M. Tawfik, A. Gamal & A. Zidan. (2014) Observational study on patients’ compliance with Irbesartan in essential hypertension “I Comply”. The Egyptian Heart Journal 66:1, pages 35-42.
Crossref
Crossref
Enrico Agabiti-Rosei, Athanasios Manolis, Dario Zava & Stefano Omboni. (2014) Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients. Advances in Therapy 31:2, pages 217-233.
Crossref
Crossref
Qi-Fang Huang, Chang-Sheng Sheng, Yan Li, Gen-Shan Ma, Qiu-Yan Dai & Ji-Guang Wang. (2013) Efficacy and Safety of a Fixed Combination of Irbesartan/Hydrochlorothiazide in Chinese Patients with Moderate to Severe Hypertension. Drugs in R&D 13:2, pages 109-117.
Crossref
Crossref
François Coudoré, Laurent Harvard, Sandrine Lefeuvre, Eliane M. Billaud, Philippe Beaune, Guillaume Bobrie, Michel Azizi, Patrice Prognon & Stéphane Laurent. (2011) HPLC–DAD Analysis of Hydrochlorothiazide and Irbesartan in Hypertensive Patients on Fixed-Dose Combination Therapy. Chromatographia 74:7-8, pages 559-565.
Crossref
Crossref
W Wang, L Ma, Y Zhang, Q Deng, M Liu & L Liu. (2010) The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. Journal of Human Hypertension 25:4, pages 271-277.
Crossref
Crossref